An indole alkaloid is a naturally occurring plant alkaloid built around an indole nucleus — a benzene ring fused to a five-membered nitrogen-containing pyrrole ring. The class is defined by this shared chemical scaffold rather than by a shared receptor target or functional effect; membership is structural, and the grouping is broad and chemically diverse.[1]
Members are biosynthesised from L-tryptophan and group into three pharmacologically distinct subgroups. The beta-carbolines — harmine and harmaline — appear in Banisteriopsis caapi and Peganum harmala. The mitragynine-type monoterpene alkaloids — mitragynine and 7-hydroxymitragynine — are the principal alkaloids of Kratom. The iboga alkaloids are represented by ibogaine from Tabernanthe iboga. Each subgroup carries the indole nucleus but converges on a different pharmacological endpoint.
Members of this class are used across traditional, recreational, and emerging therapeutic contexts. Beta-carbolines feature in Amazonian ayahuasca and Middle Eastern Syrian rue preparations. Kratom's alkaloids are consumed as a stimulant at lower exposures and as an opioid-like analgesic at higher ones. Ibogaine is used ceremonially in Bwiti tradition and investigationally as an anti-addiction agent. Effects range from mild sensory enhancement to vivid hallucinatory and oneirogenic states, with serious cardiovascular and respiratory risks appearing at the upper end of exposure for specific members.[2]
Pharmacology
Because the indole alkaloid class is defined chemically rather than pharmacologically, it does not share a single mechanism of action. What the indole scaffold does provide is a structural resemblance to serotonin and tryptophan that predisposes these molecules to engage monoaminergic systems — serotonin receptors, monoamine transporters, and monoamine-metabolising enzymes. Which target dominates is determined by the broader ring system and substituents around the indole nucleus, not by the nucleus itself.[1]
| Subgroup | Representative members | Primary pharmacological action |
|---|---|---|
| Beta-carbolines | harmine, harmaline | Reversible, competitive inhibition of monoamine oxidase A (MAO-A); minimal MAO-B activity[3] |
| Mitragynine-type MIAs | mitragynine, 7-hydroxymitragynine | Partial agonism at the µ-opioid receptor with biased G-protein signalling; 7-hydroxymitragynine carries substantially greater µ-receptor affinity than the parent compound[4] |
| Iboga alkaloids | ibogaine | Broad multi-target profile across opioid, serotonin, sigma, NMDA, and nicotinic systems; the long-lived metabolite noribogaine acts as a serotonin reuptake inhibitor and κ-opioid agonist[2][5] |
These mechanisms converge only weakly — through monoamine modulation in the broadest sense — but they diverge sharply on the endpoints that matter for safety. The beta-carbolines' MAO-A inhibition creates serotonergic and tyramine-interaction risks. The mitragynine alkaloids' opioid partial agonism creates respiratory-depression risk at high exposure. Ibogaine's multi-target profile carries a distinctive cardiac risk through hERG potassium-channel blockade. The shared indole nucleus is permissive of monoaminergic activity; the specific pharmacology — and the specific danger — belongs to each subgroup, not to the class.[6]
Substances
The members listed here fall into three subgroups, each anchored by a plant source and its principal alkaloid or alkaloids.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Harmine | Beta-carboline | The defining reversible MAO-A inhibitor of the class; the pharmacological basis of oral DMT activation in ayahuasca |
| Harmaline | Beta-carboline | More CNS-active than harmine in isolation; produces prominent tremor and hypnagogic imagery |
| Banisteriopsis caapi | Beta-carboline (plant) | The Amazonian vine that supplies the MAOI component of ayahuasca preparations |
| Peganum harmala | Beta-carboline (plant) | Middle Eastern and Central Asian source of the same beta-carbolines, used in Syrian rue and pharmahuasca preparations |
| Mitragynine | Mitragynine-type MIA | The principal alkaloid of kratom leaf; metabolised in vivo to a more potent active metabolite |
| 7-Hydroxymitragynine | Mitragynine-type MIA | A minor leaf constituent but a far more potent µ-opioid agonist; concentrated in extract preparations |
| Kratom | Mitragynine-type MIA (plant) | The Southeast Asian tree (Mitragyna speciosa) whose leaf contains both mitragynine and 7-hydroxymitragynine |
| Ibogaine | Iboga alkaloid | The principal psychoactive alkaloid of Tabernanthe iboga; investigated for anti-addictive properties |
| Tabernanthe iboga | Iboga alkaloid (plant) | A Central African shrub used ceremonially in Bwiti initiation rites and as the source of ibogaine |
These members differ in receptor target, use context, and risk profile. The indole scaffold is the chemical thread that ties them together — not a shared pharmacology, and not a shared safety profile.
Subjective Effects
Because the class is chemically rather than pharmacologically defined, the subjective profile diverges sharply by subgroup. The table below sketches characteristic effects at low, moderate-to-high, and high exposures within each subgroup; specific dose ranges belong to the member pages.
| Subgroup | Low exposure | Moderate–high exposure | High exposure |
|---|---|---|---|
| Beta-carbolines | Mild activation, subtle sensory enhancement, altered visual perception | Hypnagogic imagery, tremor (harmaline especially), elevated blood pressure | Vivid visions, marked nausea and vomiting, frank hallucinatory states |
| Mitragynine alkaloids | Stimulant-like energy, increased sociability, reduced fatigue | Shift toward analgesia, sedation, and opioid-like euphoria | Pronounced sedation and the opioid-receptor effects that follow from it |
| Iboga alkaloids | (Not typically used at sub-threshold exposures) | Ataxia, nausea, cardiovascular changes, emerging oneirogenic visions | A prolonged dissociative-oneirogenic state with autobiographical review, generally experienced as difficult rather than euphoric |
Across all three subgroups, the same physiological axes that produce the sought effects also drive the principal dangers, and the margin narrows as exposure rises. The shift is starkest for the mitragynine alkaloids, where the boundary between analgesic sedation and opioid-type respiratory depression mirrors that of classical opioids,[4] and for ibogaine, whose cardiac effects scale alongside its therapeutic ones.[6]
Safety
Risk profile
The indole alkaloid class is pharmacologically heterogeneous, and so is its acute danger. Beta-carbolines carry MAO-A interaction risks — serotonin syndrome with serotonergic drugs and hypertensive crisis with tyramine-rich foods or sympathomimetics. Mitragynine alkaloids carry opioid-receptor-mediated respiratory depression at high exposure, especially with concentrated extracts. Ibogaine causes hERG-mediated QT prolongation and has been linked to ventricular arrhythmia, torsades de pointes, and cardiac arrest — including at therapeutic doses and in people without prior cardiac disease.
The MAO-A inhibition shared by harmine and harmaline is a class-level rather than dose-level hazard: the interaction risk arises from the mechanism, not the amount. It applies whenever beta-carbolines are taken alongside SSRIs, SNRIs, MAOI-interacting foods, sympathomimetics, or other serotonergic psychoactives. In ayahuasca and pharmahuasca preparations, the same MAOI property is what permits oral activity of DMT — the pharmacology is the same; only the intent differs.[7]
The mitragynine alkaloids carry the opioid-class risk pattern, with one feature specific to this subgroup. 7-Hydroxymitragynine is substantially more potent at the µ-opioid receptor than mitragynine itself and is concentrated in extracted or refined kratom preparations, so the exposure-to-risk relationship is steeper for extracts than for traditional leaf.[4]
Ibogaine is the most acutely dangerous member of this class by a substantial margin. Its cardiac risk is mediated by hERG potassium-channel blockade and is compounded by the long half-life of its active metabolite noribogaine, so arrhythmic risk persists well beyond the acute experience. Concomitant QT-prolonging substances raise the risk further. Any ibogaine administration requires baseline ECG and continuous cardiac monitoring.[6][8]
Tolerance & dependence
Tolerance and dependence patterns track the subgroups, not the class. Tolerance to the hallucinogenic and tremor-producing effects of the beta-carbolines develops with repeated exposure, but classical physical dependence on harmine or harmaline alone is not well documented in the clinical literature; cessation does not produce a withdrawal syndrome of its own.
The mitragynine alkaloids do produce physical dependence with regular, sustained use, and the withdrawal syndrome is opioid-like in character — muscle and joint pain, lacrimation, rhinorrhoea, yawning, gastrointestinal upset, insomnia, anxiety, irritability, and dysphoria.[9] Cross-tolerance with classical opioids is documented, and buprenorphine has been used clinically to manage kratom withdrawal and dependence.[4] Self-administering kratom to manage withdrawal from other opioids tends to shift rather than resolve opioid dependence.
Ibogaine occupies a distinctive position within this class: it does not itself produce physical dependence or a withdrawal syndrome. Supervised single administrations have been associated with reduced opioid withdrawal symptoms and sustained reductions in opioid use in observational studies.[10][11] The evidence base remains small and lacks randomised controlled trials, and the cardiac risk profile means any therapeutic use must be medically supervised.
Recovery
Recovery pathways differ by subgroup. Kratom-related dependence is treatable along established opioid-use-disorder lines — a clinician can structure a buprenorphine-supported taper and longer-term support. Anyone considering ibogaine for opioid detoxification should pursue it only in a medically supervised inpatient setting with baseline ECG and continuous cardiac monitoring; self-administered ibogaine for detox carries documented lethal risk.For sustained use of MAOI-containing preparations such as Banisteriopsis caapi or Peganum harmala, the harm-reduction priority is interaction management and integration support rather than withdrawal management. A clinician or harm-reduction service can help match the right approach to the right substance.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abBerlowitz I, Egger K, Cumming P (2022) Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca — Frontiers in Pharmacology doi:10.3389/fphar.2022.886408
- [2] ^abOna, G. and Reverte, I. and Rossi, G.N. and Dos Santos, R.G. and Hallak, J.E.C. and Colomina, M.T. and Bouso, J.C. (2023) Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview — Journal of Psychopharmacology doi:10.1177/02698811231200882
- [3]
- [4] ^abcdBin Abdullah MFIL (2020) Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature — Current Drug Targets doi:10.2174/1389450121666200719011653
- [5]
- [6] ^abcMeisner, J.A. and Wilcox, S.R. and Richards, J.B. (2016) Ibogaine-associated cardiac arrest and death: case report and review of the literature — Therapeutic Advances in Psychopharmacology doi:10.1177/2045125315626073